Clinical, genetic, and pathologic characterization of FKRP Mexican founder mutation c.1387A>G
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received October 17, 2018
- Accepted in final form January 2, 2019
- First Published March 1, 2019.
Author Disclosures
- Angela J. Lee, BA*,
- Karra A. Jones, MD, PhD*,
- Russell J. Butterfield, MD, PhD,
- Mary O. Cox, BS,
- Chamindra G. Konersman, MD,
- Carla Grosmann, MD,
- Jose E. Abdenur, MD,
- Monica Boyer, NP,
- Brent Beson, MD,
- Ching Wang, MD,
- James J. Dowling, MD, PhD,
- Melissa A. Gibbons, MS,
- Alison Ballard, NP,
- Joanne S. Janas, MD,
- Robert T. Leshner, MD,
- Sandra Donkervoort, MS, CGC,
- Carsten G. Bönnemann, MD,
- Denise M. Malicki, MD, PhD,
- Robert B. Weiss, PhD,
- Steven A. Moore, MD, PhD and
- Katherine D. Mathews, MD
- Angela J. Lee, BA*,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Paul D. Wellstone Muscular Dystrophy Cooperative Research Center Grant, NIH U54 NS053672
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Karra A. Jones, MD, PhD*,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
1. NIH, NIBIB, R01EB020683, Co-investigator, 2016-2020
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Russell J. Butterfield, MD, PhD,
1) Biogen 2) Sarepta Therapeutics
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
1) NIH, NINDS 1K08NS097631-01, PI 2015-2020
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Mary O. Cox, BS,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
U54, NS053672, NIH; Wellstone Muscular Dystrophy Cooperative Research Center
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Chamindra G. Konersman, MD,
I have served on the scientific advisory board for Sarepta Pharmaceuticals and Biogen Pharmaceuticals.
NONE
NONE
NONE
NONE
NONE
NONE
Served once as a consultant in 2016 for Sarepta pharmaceuticals (commercial, for-profit). Served once as a consultant for Biogen pharmaceuticals in 2017 (commercial, for-profit).
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Carla Grosmann, MD,
I received compensation for sitting on the Sarepta scientific advisory board in July 2018, held in Santa Monica, CA.
NONE
NONE
NONE
NONE
NONE
NONE
I am a consultant(volunteer) for CureCMD a nonprofit advocacy group supporting research for Congenital Muscular Dystrophies.
NONE
NONE
NONE
NONE
NONE
Prior to September 5, 2018, I had been an employee of the University of California San Diego.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jose E. Abdenur, MD,
NONE
NONE
NONE
Journal of Inborn Errors of Metabolism and Screening (JIEMS), Editorial Board, 2013-present
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Fry Family Foundation. Research support 2013-present
NONE
NONE
NONE
NONE
NONE
NONE
- Monica Boyer, NP,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Brent Beson, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Muscular Dystrophy Association Grant for clinical support of MDA Neuromuscular Center
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ching Wang, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- James J. Dowling, MD, PhD,
(1) scientific advisory board member, RYR1 Foundation (yearly honorarium of $500 USD) (2) steering committee, MTM/CNM patient registry (3) prize committee chairperson, World Muscle Society (4) scientific advisory board member, Dynacure (yearly honorarium of $500 Euros)
(1) donation to SickKids foundation, Where There's a Will Foundation (2) donation to SickKids Foundation, Joshua Frase Foundation (3) donation to SickKids Foundation, Robbins Family Fund
(1) Audentes, travel reimbursement for investigators meeting (ASPIRO clinical trial) (2) Roche Canada, single time speaker at regional Roche conference on Spinal Muscular Atrophy
(1)Muscle and Nerve, editorial board member, 2016-present (2)PLoS Currents: Muscular Dystrophy, editorial board member, 2012-present (3) Journal of Neuromuscular Diseases, associate editor, 2014-present (4)Neuromuscular Disorders, editorial board member, 2016- present (5) Disease Models and Mechanisms, editorial board member, 2015-present
NONE
NONE
NONE
Occasional consultant, Guidepoint Global Advisors Occasional consultant, GLG group
NONE
NONE
NONE
(1) Valerion Therapeutics - grant in aid for natural history
(1) NIH 1R03AR062810 PI 3 years (2) NIH 1K08AR054835 PI 5 years (3) CIHR 324820 PI 3 years (4) CIHR 376691 PI 5 years (5) CIHR 363863 PI 5 years (6) CIHR 370710 PI 2 years (7) NSERC 5 years (8) Genome Canada DIG grant 9404 PI 2 years (9) NIH 1R21AR074006 2 years
(1) Hospital for Sick Children
(1) Muscular Dystrophy Association (MDA 186999 and MDA380397) (2) CureCMD (3) Joshua Frase Foundation (4) Team Joseph (5) Myotubular Trust (operating grant) (6) Genome Canada (7) A Foundation Building Strength
NONE
NONE
NONE
NONE
NONE
NONE
- Melissa A. Gibbons, MS,
(1)Sarepta - advisory board
NONE
(1) Avexis- compensation for time spent on educational session and travel to session
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Alison Ballard, NP,
Cure SMA Medical Advisory Board
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Joanne S. Janas, MD,
1. Sarepta Advisory Board
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Robert T. Leshner, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Sandra Donkervoort, MS, CGC,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Government employee
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Carsten G. Bönnemann, MD,
Scientific Advisory Board(1) Cure CMD, non-profit entity(2) RYR1 Foundation, non-profit entity(3) Audentes Therapeutics (no compensation)(4) DSMB for 2 Abeona Therapeutics gene therapy trials (no compensation)(5) DSMB for WAVE Therapeutics oligo therapy trial (no compensation)(6) Advisor to DSMB for Solid Therapeutics gene therapy trials (no compensation)
NONE
Has received travel expenses for lectures or educational activities not funded by industry
Co-Editor-in-Chief: Journal of Neuromuscular DiseaseEditorial Board: Matrix BiologyEditorial Board: Annals of NeurologyEditorial Board: Journal Muscle Research and Cell Motility
Listed on NINDS held patent: Diagnosing COL6-related Disorders and Methods for treating same Diagnosis and exon skipping technology for a deep intronic pseudo exon mutation in COL6A1
NONE
NONE
NONE
NONE
Principal investigator of the CALLISTO trial sponsored by Santhera Pharmaceuticals. Principal investigator of the INCEPTUS and ASPIRO trials sponsored by Audentes Therapeutics
NONE
NONE
I am an employee of the NIH and all my research funding is from intramural NIH resources
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Denise M. Malicki, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
North County Medical Office Building Ltd., 7777 Alvarado Rd. Suite 320, La Mesa, CA 92942
NONE
NONE
NONE
NONE
Veterans Medical Research Foundation, 3350 La Jolla Village Drive 151A, San Diego, CA 92161
NONE
NONE
NONE
NONE
NONE
NONE
- Robert B. Weiss, PhD,
NONE
NONE
NONE
NONE
(1) Thrombospondin-1 as a modulator of disease severity in muscular dystrophy
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) NINDS, #NS085238, PI, 2015-2018 (2) NINDS, #NS100040, PI, 2015-2018 (3) NSF, #DEB1342615, Investigator, 2015-2018
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Steven A. Moore, MD, PhD and
NONE
NONE
NONE
Brain Pathology Journal of Neuropathology and Experimental Neurology
NONE
NONE
NONE
NONE
NONE
NONE
NONE
PTC Therapeutics, Inc.; evaluating pre-treatment and post-treatment muscle biopsies; 2009-2010; fee for services contract. Sarepta Therapeutics; muscle biopsy evaluation of dystrophin using archived diagnostic biopsies; 2014-2019; fee for services contract. Flagship Biosciences; muscle biopsy evaluation of dystrophin, utrophin, and other muscle proteins using archived diagnostic biopsies; 2015-2019; fee for services contract.
U54, NS053672, NIH; Wellstone Muscular Dystrophy Cooperative Research Center; Co-Director; 2005 to present
NONE
Jain Foundation; helping develop new anti-dysferlin antibodies; 2009-2010; fee for services contract.
NONE
NONE
NONE
NONE
NONE
NONE
- Katherine D. Mathews, MD
1. DSMB, NIAMS-sponsored project 2. Santhera advisory board. travel expenses 3. Sarepta advisory board, travel expenses 4. BMS, consultant, travel expenses 5. MDA scientific advisory board
NONE
NONE
NONE
NONE
NONE
NONE
Sarepta Therapeutics Santhera
NONE
NONE
NONE
PTC Therapeutics, clinical trial site PI Sarepta Therapeutics, clinical trial site PI Pfizer, clinical trial site PI Fibrogen, clinical trial site PI Roche, clinical trial site PI Intalfarmaco, clinical trial site PI Reata, clinical trial site PI Takeda, clinical trial site PI Capricor, clinical trial site PI Catabasis, clinical trial site PI Acceleron, clinical trial site PI
1. NIH grant NIH 2 U54 NS053672-11(Muscular Dystrophy Cooperative Research Center), project PI (2015-2020); 2. Centers for Disease Control and Prevention, co-PI for site (2014-present) 3. NIH 1U24NS107181-01 (NeuroNext site), co-PI, 2018-2023
NONE
(1) Friedreich?s Ataxia Research Alliance, site PI (2007- present) Cure CMD LGMD2i Fund
NONE
NONE
NONE
NONE
NONE
NONE
- From the University of Iowa (A.J.L.), Carver College of Medicine; Department of Pathology (K.A.J., M.O.C., S.A.M.), University of Iowa; Departments of Pediatrics and Neurology (R.J.B.), University of Utah; Department of Neurology (C.G.K.), University of California San Diego; Department of Neurology (C.G.), Gillette Children's Specialty Healthcare; Division of Metabolic Disorders (J.E.A., M.B.), CHOC Children's; Department of Neurology (B.B.), Integris Southwest Medical Center; Departments of Pediatrics and Neurology (C.W.), Driscoll Children's Hospital; Departments of Paediatrics and Molecular Genetics (J.J.D.), Hospital for Sick Children, University of Toronto; Departments of Pediatrics and Neurology (M.A.G., J.S.J.), University of Colorado; Department of Physical Medicine and Rehabilitation (A.B.), University of Colorado; Department of Neurosciences (R.T.L.), University of California San Diego; National Institutes of Health (S.D., C.G.B.), Institute of Neurological Disorders and Stroke; Department of Pathology (D.M.M.), University of California San Diego; Department of Human Genetics (R.B.W.), University of Utah; and Departments of Pediatrics and Neurology (K.D.M.), University of Iowa.
- Correspondence
Dr. Jones karra-jones{at}uiowa.edu
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Nicole Sur and Dr. Mausaminben Hathidara
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Articles
Congenital muscular dystrophies with defective glycosylation of dystroglycanA population studyE. Mercuri, S. Messina, C. Bruno et al.Neurology, March 18, 2009 -
Articles
Diagnosis and etiology of congenital muscular dystrophyR. A. Peat, J. M. Smith, A. G. Compton et al.Neurology, December 26, 2007 -
Articles
New POMT2 mutations causing congenital muscular dystrophyIdentification of a founder mutationA. Yanagisawa, C. Bouchet, P.Y.K. Van den Bergh et al.Neurology, July 18, 2007 -
Article
DAG1 mutations associated with asymptomatic hyperCKemia and hypoglycosylation of α-dystroglycanMingrui Dong, Satoru Noguchi, Yukari Endo et al.Neurology, December 12, 2014